Next Article in Journal
The OncoSim Model: Development and Use for Better Decision-Making in Canadian Cancer Control
Previous Article in Journal
Toward Improved Goals-Of-Care Documentation in Advanced Cancer: Report on the Development of a Quality Improvement Initiative
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement

1
Department of Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
2
Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, ON, Canada
3
Division of Medical Oncology, Dalhousie University, Halifax, NS, Canada
4
Department of Oncology, Queen’s University, Kingston, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(6), 390-400; https://doi.org/10.3747/co.24.3757
Submission received: 5 September 2017 / Revised: 10 October 2017 / Accepted: 9 November 2017 / Published: 1 December 2017

Abstract

In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts.
Keywords: metastatic colorectal cancer; primary tumour location; tumour side; prognostic value; predictive value; egfr monoclonal antibodies; RAS wild-type; consensus statements metastatic colorectal cancer; primary tumour location; tumour side; prognostic value; predictive value; egfr monoclonal antibodies; RAS wild-type; consensus statements

Share and Cite

MDPI and ACS Style

Abrahao, A.B.K.; Karim, S.; Colwell, B.; Berry, S.; Biagi, J. The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement. Curr. Oncol. 2017, 24, 390-400. https://doi.org/10.3747/co.24.3757

AMA Style

Abrahao ABK, Karim S, Colwell B, Berry S, Biagi J. The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement. Current Oncology. 2017; 24(6):390-400. https://doi.org/10.3747/co.24.3757

Chicago/Turabian Style

Abrahao, A. B. K., S. Karim, B. Colwell, S. Berry, and J. Biagi. 2017. "The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement" Current Oncology 24, no. 6: 390-400. https://doi.org/10.3747/co.24.3757

APA Style

Abrahao, A. B. K., Karim, S., Colwell, B., Berry, S., & Biagi, J. (2017). The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement. Current Oncology, 24(6), 390-400. https://doi.org/10.3747/co.24.3757

Article Metrics

Back to TopTop